摘要
目的探讨血清生物标志物在COPD中的变化和在气流受限中的作用。方法选取稳定期COPD患者41例为COPD组，另外选取健康吸烟者35例为对照组，采用ELISA和多因子流式分析方法，测定2组人群血清肺表面活性蛋白D（pulmonary surfactant proteinD，SP-D）、基质金属蛋白酶2、3、9（matrix metalloprotease-2、3、9，MMP-2、3、9）、CXC趋化因子配体10（CXC chemokine ligand-10，CXCLl0）、Clara细胞蛋白16（Clara cell protein 16，CCl6）、可溶性晚期糖基化终产物受体（soluble receptor for advanced glycationendproducts，sRAGE）含量，完善肺功能检查并进行统计分析。结果稳定期COPD患者血清MMP-2水平较对照组减低（t=19．960，Pd0．05），MMP-3（t=44．592，P〈0．05）、CXCI．10（z=-0．263，P〈0．05）较对照组升高；2组SP-D、CCl6、sRAGE、MMP-9差异无统计学意义（P值均〉O．05）。多因素Logistic回归分析校正年龄、吸烟量等因素后显示MMP-3与COPD相关（OR-1．368，P=0．045，95％CI：1．008-1．858）。在COPD患者中偏相关性分析发现MMP-3与FVC％pred、FEVl％pred、FEVl／FVC、MMEF％均无相关性（P值均〉O．05）。随着疾病加重血清MMP-3水平变化差异无统计学意义（P〉0．05）。结论血清MMP3可能在气流受限中起作用，有可能对COPD有诊断价值，但本研究中与COPD患者气流受限程度关系不大。
Objective To investigate the changes of serum biomarkers in chronic obstructive pulmonary disease （COPD） and their role in airflow limitation. Methods Forty-one patients with COPD were selected as COPD group and 35 healthy smokers were selected as control group. We quantified serum levels of pulmonary surfactant protein D （SP-D）, matrix metalloproteinase 2, 3, 9 （MMP-2, 3, 9）, CXC chemokine ligand 10 （CXCL10）, Clara cell protein 16 （CC16）, soluble receptor for advanced glycation end products （sRAGE） and pulmonary function. Results The level of serum MMP-2 in patients with stable COPD was lower than that in control group（ P 〈0.05）, MMP-3 and CXCL10 were higher than those in the control group（both P d0.05）, SP-D, CC16, sRAGE and MMP-9 were not statistically significant （all P〉0.05）. Multivariate logistic regression analysis showed that MMP-3 was associated with COPD after adjustment for age, smoking and other factors （ OR = 1. 368, P = 0. 045, 95 % CI ： 1. 008-1. 858）. The correlation analysis showed that MMP-3 had no correlation with FVC% pred, FEV1% pred, FEV1/FVC and MMEF% （all P〉0.05）. There was no significant difference in serum MMP-3 level with the increase of disease （ P 〉0.05）. Conclusions Serum MMP-3 may play a role in airflow limitation and may have diagnostic value for COPD, but this study has little to do with the degree of airflow limitation in COPD patients.
出处
《国际呼吸杂志》
2017年第9期653-658,共6页
International Journal of Respiration
基金
国家自然科学基金（81270097、81470235、81670034）
关键词
慢性阻塞性肺疾病
生物标志物
肺功能
基质金属蛋白酶3
气流受限
Chronic obstructive pulmonary disease
Biomarker
Pulmonary function
Matrixmetalloproteinase-3
Airflow limitation
